Annexin A2: A tissue plasminogen activator amplifier for thrombolytic stroke therapy

Stroke

Volumn 41, Issue 10 SUPPL. 1, 2010, Pages

  Fan, Xiang ^a   Yu, Zhanyang ^a   Liu, Jianxiang ^a   Liu, Ning ^a   Hajjar, Katherine A ^b   Furie, Karen L ^a   Lo, Eng H ^a   Wang, Xiaoying ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

annexin A2; cerebral ischemia; combination therapy; thrombolysis; tPA

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOLYTIC AGENT; LIPOCORTIN 2; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT ANNEXIN A2; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PERFUSION; COMPLEX FORMATION; CONFERENCE PAPER; DIFFUSION WEIGHTED IMAGING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; LOW DRUG DOSE; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; RECANALIZATION; STROKE; TREATMENT OUTCOME; ANIMAL; DRUG COMBINATION; PILOT STUDY; PROCEDURES;

ANIMALS; ANNEXIN A2; BRAIN ISCHEMIA; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; PILOT PROJECTS; RATS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77957979815     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.596106     Document Type: Conference Paper

References (40)

1. Thomalla G, Schwark C, Sobesky J, Bluhmki E, Fiebach JB, Fiehler J, Zaro Weber O, Kucinski T, Juettler E, Ringleb PA, Zeumer H, Weiller C, Hacke W, Schellinger PD, Rother J. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a german multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke. 2006;37:852-858.
2. Marks MP, Olivot JM, Kemp S, Lansberg MG, Bammer R, Wechsler LR, Albers GW, Thijs V. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the defuse study. Radiology. 2008;249:614-623.
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
4. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab. 2004;24: 945-963.
5. Armstead WM, Ganguly K, Kiessling JW, Chen XH, Smith DH, Higazi AA, Cines DB, Bdeir K, Zaitsev S, Muzykantov VR. Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab. 2009;29:1463-1474.
6. Nassar T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M, Heyman SN, Higazi AA. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood. 2004;103:897-902.
7. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001; 7:59-64.
8. Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9:1313-1317.
9. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004;35: 2726-2730.
10. Benchenane K, Lopez-Atalaya JP, Fernandez-Monreal M, Touzani O, Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 2004;27:155-160.
11. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci. 2009;32:48-55.
12. Marder VJ, Stewart D. Towards safer thrombolytic therapy. Semin Hematol. 2002;39:206-216.
13. Davalos A. Thrombolysis in acute ischemic stroke: successes, failures, and new hopes. Cerebrovasc Dis. 2005;20(suppl 2):135-139.
14. Ding G, Jiang Q, Zhang L, Zhang ZG, Li L, Knight RA, Ewing JR, Wang Y, Chopp M. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor. J Cereb Blood Flow Metab. 2005; 25:87-97.
15. Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2000;20:452-457.
16. Armstead WM, Nassar T, Akkawi S, Smith DH, Chen XH, Cines DB, Higazi AA. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci. 2006;9:1150-1155.
17. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Micro-plasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke. 2002;33:2279-2284.
18. Lapchak PA, Song D, Wei J, Zivin JA. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol. 2004;188:279-285.
19. Ranby M, Brandstrom A. Biological control of tissue plasminogen activator-mediated fibrinolysis. Enzyme. 1988;40:130-143.
20. Wang X, Rosell A, Lo EH. Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy. CNS Neurol Disord Drug Targets. 2008;7:235-242.
21. Kim J, Hajjar KA. Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci. 2002;7:d341-d348.
22. Hajjar KA, Menell JS. Annexin II: a novel mediator of cell surface plasmin generation. Ann N Y Acad Sci. 1997;811:337-349.
23. Siever DA, Erickson HP. Extracellular annexin II. Int J Biochem Cell Biol. 1997;29:1219-1223.
24. Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphor-ylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem. 2004;279:43411-43418.
25. Hajjar KA, Acharya SS. Annexin II and regulation of cell surface fibri-nolysis. Ann N Y Acad Sci. 2000;902:265-271.
26. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest. 2004;113:38-48.
27. Ishii H, Yoshida M, Hiraoka M, Hajjar KA, Tanaka A, Yasukochi Y, Numano F. Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ Res. 2001;89:1240-1245.
28. Tanaka Y, Ishii H, Hiraoka M, Miyasaka N, Kuroiwa T, Hajjar KA, Nagaoka T, Duong TQ, Ohno K, Yoshida M. Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: a magnetic resonance imaging study. Brain Res. 2007;1165:135-143.
29. Lo EH, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metallopro-teinases. J Neurosci Res. 2002;69:1-9.
30. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem. 1994;269:21198-21203.
31. Zhu H, Fan X, Yu Z, Liu J, Murata Y, Lu J, Zhao S, Hajjar KA, Lo EH, Wang X. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab. 2010;30:1137-1146.
32. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981;46:561-565.
33. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost. 2001;86:739-745.
34. Benchenane K, Berezowski V, Fernandez-Monreal M, Brillault J, Valable S, Dehouck MP, Cecchelli R, Vivien D, Touzani O, Ali C. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke. 2005;36:1065-1070.
35. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood- brain barrier via the LDL receptor-related protein. J Clin Invest. 2003;112:1533-1540.
36. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke. 2002;33:2711-2717.
37. Zhang C, An J, Strickland DK, Yepes M. The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain. Am J Pathol. 2009; 174:586-594.
38. Jacovina AT, Deora AB, Ling Q, Broekman MJ, Almeida D, Greenberg CB, Marcus AJ, Smith JD, Hajjar KA. Homocysteine inhibits neoangio-genesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest. 2009;119:3384-3394.
39. Hajjar KA, Krishnan S. Annexin II: a mediator of the plasmin/plasmin-ogen activator system. Trends Cardiovasc Med. 1999;9:128-138.
40. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation. 1995;92:1883-1890.